Tetherin (Bst-2 CD317) is a cell-surface protein whose expression is induced by IFNα. Although tetherin expression causes the retention of retrovirus particles on the surface of infected cells, it is not known whether tetherin inhibits retroviral replication or pathogenesis in vivo. Mutation of tetherin antagonists often has little effect on retroviral replication in vitro, and, although tetherin can reduce the yield of extracellular viral particles, some studies suggest that tetherin actually enhances direct cell-to-cell viral transmission. We generated tetherin-deficient mice to determine the effect of this protein on murine retrovirus replication and pathogenesis. We find that tetherin markedly inhibits the replication of Moloney murine leukemia virus (Mo-MLV) and is required for the antiretroviral activity of IFNα to be fully manifested in vitro. Surprisingly, Mo-MLV replication and disease progression was not significantly different in WT and tetherin-deficient mice, but this finding was explained by the fact that Mo-MLV infection did not induce detectable tetherin expression on candidate target cells in vivo. Indeed, IFNα induction was required to reveal the antiMo-MLV activity of tetherin in vivo. Moreover, LP-BM5, an MLV strain that has been demonstrated to induce immune activation and IFNα expression, achieved higher levels of viremia and induced exaggerated pathology in tetherin-deficient mice. These data indicate that tetherin is a bona fide antiviral protein and can reduce retroviral replication and disease in vivo.
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M ammals encode an array of molecules that can be constitutively expressed or induced by IFNs and have been demonstrated or suspected to have direct antiretroviral activity. One such molecule is tetherin, an unusual type I IFN-induced membrane protein that has both transmembrane and glycophosphatidylinositol membrane anchors (1, 2) . Tetherin was first demonstrated to cause the retention of HIV-1 and Moloney murine leukemia virus (Mo-MLV) particles on the surface of infected cells (3, 4) , but subsequent studies have shown that it can induce the retention of a variety of enveloped virus particles, including widely divergent representatives of the retrovirus, filovirus, rhabdovirus, arenavirus, and herpesvirus families (5) (6) (7) (8) . Mechanistic studies have shown that virion retention occurs after the infiltration of their lipid envelopes by the tetherin protein itself, which leads to the tethering of virions on the surface of infected cells (9) (10) (11) .
There is as yet no evidence that tetherin influences viral replication and pathogenesis in vivo. Indeed, some studies suggest that tetherin does not inhibit, and can even enhance, the transmission of HIV-1 from infected cells to neighboring uninfected cells by concentrating virions at the cell surface and enhancing the formation of so-called "virological synapses" (12) . Because a significant proportion of cell-to-cell retroviral transmission in vitro and in vivo may occur via direct cell contact (13) (14) (15) (16) and because deletion of the tetherin antagonist, Vpu, from the HIV-1 genome has little effect on replication in some cell-culture assays (17) , the role of tetherin as an antiviral factor in vivo is uncertain (18, 19) . Moreover, some studies suggest that tetherin has immunomodulatory rather than direct antiviral activity (20, 21) .
In this study, we use tetherin-deficient cells and animals to examine the role of tetherin in inhibiting retroviral replication in vitro and in mediating the antiretroviral activity of IFNα. We demonstrate that tetherin has potent antiretroviral activity in vitro and is required for the full antiretroviral activity of IFNα both in vitro and in vivo. Moreover, although tetherin in not required for the development of a normal murine immune system, its absence can exacerbate the replication and pathogenesis of a murine retrovirus.
Results
Tetherin Potently Inhibits Retroviral Replication in Vitro. Tetherin is constitutively expressed on a few cell types (e.g., plasmacytoid dendritic cells, plasma B cells) but is absent from many others in mice (20) . However, its expression is induced by type I IFN in a wide range of cells (20) . Because tetherin is one of many IFNstimulated genes (ISGs) that are possible effectors of IFN's antiretroviral activity, we first determined whether and how IFNα inhibits the replication of a murine retrovirus (Mo-MLV) in cell culture and what role, if any, tetherin plays in the in vitro antiretroviral activity of IFNα. Mo-MLV replication in NIH/3T3 cells was potently inhibited by IFNα, with yields of virus reduced by 10-to 100-fold over 5 d of replication (Fig. 1A) . Notably, tetherin was not constitutively expressed on NIH/3T3 cells but was strongly induced by treatment with IFNα (Fig. 1B) . We generated a panel of NIH/3T3-derived cell lines, each expressing a different level of murine tetherin, some of which closely matched those on IFNα-treated cells (Fig. 1C) . Mo-MLV replication in these cell lines, as measured by the levels of infectious virus in culture supernatants, correlated inversely with the level of tetherin expression ( Fig. 1 D  and E) . Strikingly, Mo-MLV replication in IFNα-treated NIH/3T3 cells was similar in magnitude to that in cells that were not treated with IFNα but expressed similar levels of tetherin ( Fig. 1 D and E) , suggesting that tetherin could be a major contributor to the antiretroviral activity of IFNα in vitro.
Generation and Characterization of Tetherin-Deficient Mice. To determine whether tetherin is indeed a key effector of the antiretroviral action of type I IFN, we generated tetherin-deficient mice (Fig. S1 ). To accommodate the possibility that tetherin might have some essential function in mice, a conditional knockout (CKO) strategy was adopted, whereby sequences comprising the majority of exon 1 (which encodes the transmembrane and the bulk of the extracellular domain) were flanked by loxP sites (Fig.  S1A) . However, tetherin-null mice, resulting from breeding tetherin CKO mice to mice expressing Cre under the control of a promoter expressed in the germ line ( Fig. 1 A and B), were fertile, had no apparent physical or behavioral deficits, and were born at the expected frequency ( Fig. S1 D and E). Tetherindeficient mice had numbers of total splenocytes, thymocytes, and bone marrow cells that were similar to those of WT animals and had normal proportions of splenic CD3 + , B220 + , CD11b + , and CD11c + cells ( This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: pbienias@adarc.org.
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( Fig. S2B ). Tetherin-deficient mice also had normal percentages of bone marrow erythromyeloid progenitor and hematopoietic progenitor cell populations (MP and LSK, respectively, in Fig.  S2C ). Plasmacytoid dendritic (Siglec-H + ) cells, which normally express high levels of tetherin, were also found at normal frequencies ( Fig. S2A ) but, importantly, were devoid of cell-surface tetherin when they were harvested from tetherin-deficient donors (Fig. S2D) . Thus, the absence of tetherin appeared to be fully compatible with the development of the major organ systems of mice, and, in particular, no apparent perturbations of the immune system occurred as a consequence of tetherin deletion. Importantly, tetherin-deficient cells responded similarly to WT cells when stimulated with Toll-like receptor (TLR) 3, 7, and 9 agonists in vitro (Fig. S3 ), suggesting that there was no functional impairment in the activation of these cells in the absence of tetherin.
Tetherin Is Required for the Full Antiretroviral Activity of IFNα in
Vitro. Tetherin was not expressed at detectable levels on murine embryonic fibroblasts (MEFs) derived from WT or tetherindeficient mice ( Fig. 2A) , which each supported similar levels of Mo-MLV replication in vitro ( Fig. 2 B and C) . Conversely, tetherin was strongly induced in WT (but not tetherin-deficient) MEFs when they were treated with IFNα ( Fig. 2A) . Notably, IFNα potently inhibited the replication of Mo-MLV in WT MEFs, but its antiviral efficacy was greatly reduced in tetherindeficient MEFs, although there was some residual antiviral activity of IFNα in the absence of tetherin (Fig. 2 B and C) . Thus, tetherin expression was sufficient to recapitulate the effect of IFNα on Mo-MLV replication and necessary for the full effect of IFNα on Mo-MLV replication to be manifested in cultured cells.
Tetherin Is Constitutively Expressed on Few Cells in Vivo and Is Not
Induced by Mo-MLV Infection. Mo-MLV infection of neonatal C57BL/6 mice gives rise to large numbers of infected cells in bone marrow, spleen, and thymus at 8 d after infection (Fig. 3A) , with tumors (mostly of T-cell origin) becoming obvious and eventually fatal at 100-300 d after challenge (Fig. 3B) . Surprisingly, upon Mo-MLV infection of neonates, the numbers of Mo-MLVinfected cells did not differ in WT or tetherin-deficient littermates at 8 d after infection (Fig. 3A) . Moreover, mice succumbed to Mo-MLV-induced disease at approximately the same rate, irrespective of tetherin genotype (Fig. 3B) . This finding at first suggested that tetherin had little effect on Mo-MLV replication in vivo, despite being an effective inhibitor in vitro (Fig. 1) .
Because tetherin exhibited a clear antiretroviral activity in vitro but not, apparently, in vivo, we next asked whether tetherin was expressed on cells that are infected with Mo-MLV in mice. In fact, the majority of cells harvested from bone marrow of mice did not express tetherin (Fig. S4) , and 12 d of Mo-MLV infection did not induce up-regulation of tetherin expression (Fig. 3C ), despite the fact that infectious center assays suggested that a large fraction (∼10-100%) of splenocytes, thymocytes, and bone marrow cells were infected with Mo-MLV at this time point (Fig. S5) . Altogether, these data suggested the possibility that Mo-MLV replication and pathogenesis in vivo is not affected by tetherin, at least in part because Mo-MLV replication does not induce a robust type I IFN response and, perhaps as a consequence, the bulk of Mo-MLV replication occurs in cells that do not express tetherin. This hypothesis was supported by the fact that IFNα receptordeficient mice developed lethal Mo-MLV-induced disease with similar kinetics to WT mice (Fig. 3D) .
Induction of Tetherin Expression Reveals Its Antiretroviral Activity in
Vivo. To determine whether tetherin could exert an antiretroviral effect in vivo if its expression was induced by stimulating a type I IFN response, we treated Mo-MLV-infected mice with polyinosinic:polycytidylic acid [poly(I:C)], a type I IFN inducer, and measured release of virus into plasma a short time (24 h) later. Poly(I:C) caused up-regulation of tetherin on various cell types ( Fig. 4 A and B) , including T cells, which are thought to be the preferred target for Mo-MLV replication. Importantly, both WT and tetherin-deficient mice responded similarly to poly(I:C) treatment (Fig. 4 D-G) by up-regulating several activation markers, with the obvious exception of tetherin (Fig. 4C) . Additionally, the poly(I:C)-induced activation, including tetherin upregulation, depended on type I IFN signaling, as demonstrated by the absence of cell activation in IFN (α, β, and ω) receptor 1 (IFNAR1)-deficient animals (Fig. 4 C-G) . These data suggested that, with the exception of tetherin up-regulation, the response to poly(I:C) was unaffected in tetherin-deficient mice. Although plasma viremia was highly variable in cohorts of Mo-MLV-infected animals, there was no significant difference in plasma viremia in tetherin-deficient mice compared with WT or heterozygous littermates at 12 d after infection (Fig. 5A) . However, when animals were treated with a single dose of poly(I:C) at 12 d after infection and then measured for plasma viremia the following day, the level of plasma viremia was significantly higher (∼fivefold, P < 0.05) in tetherin-deficient mice compared with WT littermates (Fig. 5B) .
Tetherin-Deficient Mice Exhibit Exacerbated Murine AIDS VirusInduced Disease. These accumulated data indicated that tetherin is not required for the development and function of the immune system, but it can indeed inhibit the release and replication of Mo-MLV in vitro and in vivo, provided that its expression is induced in cells in which the virus is replicating. We next determined whether tetherin could influence replication and the course of disease during retroviral infection without the need for an intervention [e.g., poly(I:C) treatment] to stimulate its expression. To do so, we used a different MLV, termed LP-BM5, that induces immune activation, polyclonal B-cell proliferation, and impaired immune responses and is sometimes referred to as the murine AIDS virus because of superficial similarities in the aforementioned pathogenesis to that of HIV infection in humans (22, 23) . Moreover, previous studies have shown that LP-BM5 induces the expression of type I IFN in infected mouse tissues at later time points (∼8 wk after infection) (24) Consistent with this finding, tetherin expression was found to be up-regulated in the splenocytes of LP-BM5-infected WT mice at 14 wk after infection compared with uninfected WT controls (Fig. S6) . In vitro experiments revealed that LP-BM5 replication was inhibited by tetherin to a similar extent as Mo-MLV replication, as expected (Fig. 6A) . Although infection of WT and tetherin-deficient mice with LP-BM5 resulted in similar levels of plasma viremia at early time points, measurements at later times (>8 wk) after infection, when type I IFN is induced (24) and tetherin up-regulation is evident (Fig. S6) , showed a clear effect of tetherin on LP-BM5 replication. Specifically, viremia peaked at 9 to10 wk after infection and was ∼10-to 100-fold higher in tetherin-deficient mice compared with WT controls (Fig. 6B) . Shortly thereafter, tetherin-deficient mice became moribund and they, along with WT controls, were killed at 14 wk after infection. Inspection of lymphoid tissues from age-matched uninfected WT and tetherindeficient mice revealed no changes in uninfected mice as a result of the presence or absence of tetherin ( Fig. 6 C-F) . However, the splenomegaly and lymphadenopathy that accompanies LP-BM5 infection was significantly exaggerated in the tetherin-deficient mice, with up to twofold greater mean spleen and lymph node weights compared with infected WT controls (Fig. 6 C-F) . Overall, assessment of both virological and pathologic parameters revealed clearly greater viral replication and more aggressive LP-BM5-induced disease progression in the absence of tetherin.
Discussion
These data demonstrate that tetherin inhibits the replication of murine retroviruses both in vitro and in vivo. However, it appears that some retroviruses (e.g., Mo-MLV) encounter tetherin rather infrequently in vivo because its presence or absence did not affect Mo-MLV replication or pathogenesis in vivo. Because previous work has indicated that the in vivo replication of murine retroviruses is limited by adaptive immune responses (25) , this finding, along with extensive immunophenotyping, strongly suggests that tetherin is not required for the development of a functional adaptive immune system. Furthermore, our findings suggest that Mo-MLV replicates in vivo without inducing a robust IFN response and evades a molecule that would otherwise profoundly limit its replication simply by not inducing its expression.
Many other enveloped viruses, including HIV-1 and simian immunodeficiency virus, induce a robust type I IFN response (26, 27) . As such, these viruses are likely to frequently encounter tetherin (28, 29) , and their replication is consequently inhibited. Indeed, this appears to be the situation for LP-BM5, whose replication and pathogenesis are attenuated by tetherin (Fig. 6) . The elevated replication of LP-BM5 in tetherin-deficient mice could be attributable to both induction of type I IFN and infection of plasma B cells (22, 30) , one of the few cell types that constitutively expresses tetherin in mice. Several viruses have evolved to antagonize tetherin function (in the case of HIV-1 and simian immunodeficiency virus with their Vpu, Nef, and envelope proteins) (3, (31) (32) (33) (34) , underscoring its potential role in limiting viral replication in vivo. Overall, it appears that tetherin has arisen in mammals primarily, and likely exclusively, as a directly acting innate protection against viral disease.
Materials and Methods
Generation of Tetherin-Deficient Mice. A targeting construct was generated containing a Neo cassette flanked by 2 FRT sites and loxP sites flanking the first exon of the tetherin gene (Fig. S1A) . Founder mice were crossed to FLP1 transgenic mice, creating the tetherin CKO allele (Bst2 
